-
Professor Renu Eapen: New Advances and Future Perspectives in Radioligand Therapy for Prostate Cancer
Highlights from the 15th Shanghai Urologic Oncology Academic Conference Captions are auto generatedPlay Editor’s Note: Over the past decade, the treatment landscape of prostate cancer has undergone profound transformation, with…
-
Professor Ming Liu’s Team Establishes MRI-Based Criteria for Assessing the Difficulty of Intrafascial Excision and Nerve Preservation
Highlights from the 15th Shanghai Urologic Oncology Academic Conference Editor’s Note: The 15th Shanghai Urologic Oncology Academic Conference was grandly held in Pudong, Shanghai, bringing together leading experts in urology…
-
Lymphoma Roundtable · ASH Special | Professor Cai Qingqing: New Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma
The 2025 Annual Meeting of the American Society of Hematology (ASH 2025) has recently concluded successfully in Orlando, USA. As the “grand finale” of the hematology field each year, this meeting showcased a series of cutting-edge breakthroughs in lymphoma research, providing new directions for optimizing clinical practice.
-
Voice of China at ASH | Professor Zou Dehui: With Early Prediction and Patient Selection, CAR-T Therapy Will Deliver Greater Value in R/R DLBCL
From December 6–9, 2025, the 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando, USA. As the world’s largest and most influential international conference in hematology, ASH attracts tens of thousands of experts and scholars each year to share the latest advances and breakthrough research in the field.
-
Global Perspectives at ASH |Professor Othman Al-Sawaf: The CLL17 Trial Redefines the Treatment Paradigm—Fixed-Duration Therapy Is Non-Inferior to Continuous Treatment
The widespread adoption of targeted therapies has significantly improved long-term outcomes for patients with chronic lymphocytic leukemia (CLL). However, a critical question has remained unanswered: Is fixed-duration therapy as effective as continuous treatment? Until now, no prospective head-to-head evidence had directly compared these two strategies.
-
Lymphoma In-Depth Conversations · ASH Special | Professor Qingqing Cai: New Advances in First-Line Treatment of Follicular Lymphoma
The 2025 Annual Meeting of the American Society of Hematology (ASH 2025) has recently concluded in Orlando, USA. As the “year-end flagship event” in hematology, this year’s meeting presented a…
-
Prof. Wojciech Jurczak on the BRUIN CLL-313 Study and First-Line CLL Treatment
In this video from ASH, Prof. Wojciech Jurczak, consultant hematologist and Head of Department at the Maria Skłodowska-Curie National Research Institute of Oncology, shares key results from the randomized BRUIN…
-
Prof. Othman Al-Sawaf on Fixed-Duration vs Continuous Therapy in CLL
In this video, Prof. Othman Al-Sawaf, hematologist and clinical investigator at the University Hospital Cologne and the German CLL Study Group, shares key findings from a randomized study comparing fixed-duration…
Connecting Medical Expertise through Media